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Key messages
What is already known about this subject?
 ► neutropaenia is a recognised finding in the context 
of rheumatoid arthritis (ra).
 ► However its frequency and characteristics are not 
well defined, particularly in early ra.
What does this study add?
 ► neutropaenia is examined in a real-world early ra 
cohort with longitudinal follow-up.
 ► Frequency (~7.5%), predicting factors (low neu-
trophils at baseline, non-smoking, female gender), 
natural history (usually mild, possibly relating to 
medications) and outcome (not leading to increased 
rates of infections or other adverse outcomes) are 
described.
How might this impact on clinical practice?
 ► careful monitoring of patients with early ra for neu-
tropaenia is recommended, particularly those with 
adverse predicting factors.
AbstrAct
Objectives to determine the frequency, severity and 
natural history of neutropaenia in early rheumatoid arthritis 
(ra), explore its associations with clinical features and 
assess its impact on clinical management.
Methods the Scottish early rheumatoid arthritis 
inception cohort prospectively recruited patients with 
newly diagnosed ra and followed them up every 6 
months. Patients with ra who developed at least one 
episode of neutropaenia (grade 1: <2.0×10^9/l; grade 
2: <1.5×10^9/l; grade 3: <1.0×10^9/l; grade 4: 
<0.5×10^9/l) were compared with those who did not. 
comparisons were also made between patients who 
experienced one or more episodes of neutropaenia and 
between patients with different neutropaenia grades.
Results 77 neutropaenia episodes were recorded in 58 
of 771 (7.5%) patients with ra, who were followed up 
for a median (range) of 18 (6–48) months. neutropaenia 
occurred at a median (range) of 12 (0–120) months after 
ra diagnosis. the majority had mild neutropaenia (grade 
1: n=42; grade 2: n=14; grade 3: n=1; grade 4: n=1). 
neutropaenia was transient (single episode) in the majority 
(44; 75.8%) of cases but led to treatment discontinuation 
in 14 (24.1%) patients. Patients who developed 
neutropaenia were more likely to be female (p=0.01) and 
non-smokers (p=0.007) and had lower baseline neutrophil 
levels (p<0.0001). Binomial regression analysis confirmed 
the latter (p<0.0001, B: −0.491) as neutropaenia predictor. 
the rate of infections did not differ between patients who 
developed neutropaenia and those who did not (p=0.878).
Conclusion neutropaenia was a common finding in this 
cohort. it was usually mild, transient and not associated 
with increased infection rates. neutropaenia occurrence 
was associated with non-smoking, female gender and 
lower baseline neutrophil levels.
InTROduCTIOn
Neutropaenia is a recognised finding in 
the context of rheumatoid arthritis (RA). 
Surprisingly, its actual incidence and clin-
ical impact have not been well described 
despite its rather common occurrence in 
routine care.1–4 There are various potential 
factors contributing to neutropaenia in RA, 
including drugs (conventional and biologic 
disease-modifying antirheumatic drugs 
(DMARDs)), autoimmune mechanisms (eg, 
Felty’s syndrome), coexistent viral infections, 
and other conditions like large granulocytic 
lymphocytic leukaemia.5 6 Relatively few 
studies have been published investigating 
the frequency of neutropaenia in RA. Most 
of these are for patients with RA treated with 
specific medications or retrospective data-
base studies,1 3 4 7–14 while one study reported 
the prevalence of baseline neutropaenia in 
patients with untreated RA.2 To the best of 
our knowledge, no studies have examined 
the occurrence of neutropaenia in a national 
real-world inception cohort of patients with 
RA with longitudinal follow-up.
The aim of our study was first to determine 
the frequency and severity (grade) of neut-
ropaenia in patients with early RA. Second, 
we wished to explore possible associations 
with clinical or laboratory manifestations and 
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with conventional DMARDs treatment. We also aimed 
to investigate if there were any potential predictors for 
its occurrence. Finally, we explored the natural history 
of neutropaenia in RA (ie, transient or recurrent) and 
the effect on patients’ management (permanent or 
temporal treatment discontinuation) and susceptibility 
to infections.
PaTIenTs and MeTHOds
Cohort description
Data were obtained from the Scottish Early Rheumatoid 
Arthritis (SERA) inception cohort, which prospectively 
recruited patients with new-onset RA and undifferenti-
ated arthritis (≥1 swollen joint) between 2011 and 2015 
attending rheumatology centres across Scotland.15 Partic-
ipants in SERA were treated by their usual rheumatology 
team as per standard clinical practice, independent of 
their participation in the cohort. This current study eval-
uated participants in SERA who fulfilled the American 
College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) 2010 criteria for RA16 at the 
baseline visit. Patients with an alternative autoimmune 
rheumatic diagnosis at baseline, patients whose diag-
nosis was revised to another rheumatic disease during 
follow-up or patients who had previously received any 
DMARD were excluded.15
A range of prespecified features were recorded at 
the baseline visit and then at 6-monthly follow-up visits, 
including clinical (coexistent medical conditions, medi-
cation being received for RA or other diseases), demo-
graphic (age, gender, height, weight, smoking status, 
alcohol consumption, employment status) and labora-
tory (full blood count, biochemistry profile, acute phase 
reactants, rheumatoid factor and anti-Cyclic Citrulli-
nated Peptide (CCP) (assessed by fluorescence-based 
ELISA using second-generation CCP)) parameters and 
disease activity indices (Disease Activity Score in 28 joints 
(DAS28), Clinical Disease Activity Index (CDAI), Simple 
Disease Activity Index (SDAI)). Patients included in this 
study had at least two sets of laboratory results recorded, 
while those with no neutrophil count available were 
excluded. The baseline characteristics of the cohort have 
been previously described.15 Written informed consent 
was obtained from all participants.
study design
SERA participants with RA who developed at least one 
episode (defined as a data entry in SERA database) 
of neutropaenia (grade 1: 1.5–2.0×10^9/L; grade 2: 
1.5–1.0 ×10^9/L; grade 3: 1.0– 0.5×10^9/L; grade 4: 
<0.5×10^9/L) were identified. Their demographic, clin-
ical and laboratory characteristics at baseline, as well 
as throughout the total follow-up time, were compared 
with those of patients with RA who never had a recorded 
episode of neutropaenia. Comparisons were also made 
between patients with a single recorded episode of 
neutropaenia (transient) and those who had more than 
one episode recorded (recurrent), and between patients 
with different grades of neutropaenia.
Leucopaenia was defined as a total white cell count 
<4.0×10^9/L; lymphopaenia as lymphocytes <1.0×10^9/L; 
thrombocytopaenia as platelets <100×10^9/L, and 
anaemia as haemoglobin <120 g/L for women and <135 
g/L for men. Total follow-up time was defined as the time 
interval between the time of the RA diagnosis and the 
last follow-up visit for the SERA study. Infections tempo-
rally associated with neutropaenia were defined as those 
recorded in the database occurring within 3 months 
prior to or after the recorded episode of neutropaenia.
statistics
Two-sided Fisher’s exact and Mann-Whitney tests were 
used to compare categorical and numerical character-
istics, respectively. Benjamini-Hochberg correction was 
applied for multiple comparison correction for a false 
discovery rate of 0.25.17 In detail, Benjamini-Hochberg 
procedure was performed as follows: p values of compar-
isons in the same category (eg, baseline laboratory char-
acteristics from table 1) were placed in ascending order 
and a rank was assigned to each p value, starting from the 
smallest p value. Corrected p value (also known as critical 
value) was calculated using the formula (i/m)Q, where 
‘i’ is the rank of the p value, ‘m’ the total number of tests 
and ‘Q’ the false discovery rate. In our study, this latter 
was preset to 0.25. The largest p value that was smaller 
than the critical value was then marked. All the values, 
smaller than the latter, were considered statistically 
significant. In our study, no significant p value became 
insignificant after correction for multiple comparison. 
A binary logistic regression analysis (enter model) was 
performed using the occurrence of neutropaenia as 
the dependent variable, and 13 predefined clinical and 
laboratory features (age, gender, smoking status, alcohol 
consumption, seropositivity, baseline cytopaenias, base-
line neutrophil number and treatment being received 
for RA) as independent variables. Patients with neutro-
paenia at the baseline visit (n=5) were excluded from the 
latter analysis. Possible interaction between relevant vari-
ables (ie, smoking status by gender and smoking status 
by baseline neutrophil levels and gender by baseline 
neutrophil levels) was also checked. Statistical analysis 
was performed using SPSS V.21.0 software.
ResulTs
Cohort description
Of the total 913 patients with RA in SERA, 142 were 
excluded because of missing laboratory values, as 
described above. Seven hundred and seventy-one patients 
with RA (ACR/EULAR 2010 criteria) were available for 
evaluation, with follow-up data available for a median 
(range) time of 18 (6–48) months. Comparison of the 
excluded patients with the group of those included in 
the study did not reveal any differences (online supple-
mentary table 1). The baseline characteristics of the 
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Table 1 Baseline demographic and laboratory characteristics of patients with RA included in this data set
Patient characteristics
Neutropaenic
n=58
Non–neutropaenic
n=713 P values
Demographic
  Age,* mean±SD 57.7±14.1 58.8±13.4 0.538
  Female gender, n (%) 47 (81.0) 460 (64.5) 0.010
  Total follow-up (months), median (range) 18 (6–48) 18 (6–48) 0.139
  Smoking, n (%) 6 (10.3) 188 (26.4) 0.007
  Alcohol consumption, n (%) 40 (69.0) 421 (57.9) 0.127
Laboratory
  Anaemia,† n (%) 7/55 (12.7) 142/702 (20.2) 0.218
  Thrombocytopaenia,‡ n (%) 0/55 (0.0) 0/702 (0.0) 1.000
  Leucopaenia,§ n (%) 1/55 (1.8) 3/702 (0.4) 0.261
  Lymphopaenia,¶ n (%) 4/55 (7.2) 40/702 (5.7) 0.520
  Neutrophils number, mean±SD (×10^9/L)** 4.29±2.12 5.89±2.15 <0.0001
  RF-positive, n (%) 27/35 (77.1) 284/428 (67.1) 0.262
  Anti-CCP-positive, n (%) 35/46 (74.4) 410/587 (69.8) 0.620
  Baseline DAS28, mean±SD 4.76±1.51 5.04±1.38 0.310
*Age at the time of RA diagnosis.
†Haemoglobin <135 g/L for men and haemoglobin <120 g/L for women.
‡Platelets <100×10^9/L
§White cell count: <4×109/L.
¶Lymphocytes: <1×109/L.
**n=53 (5 patients had neutropaenia at baseline).
CCP, Cyclic Citrullinated Peptide; DAS28, Disease Activity Score in 28 joints; RA, rheumatoid arthritis; RF, rheumatoid factor.
participants included in the analysis, with and without at 
least one episode of neutropaenia, are shown in table 1.
neutropaenia frequency and severity
A total of 77 episodes of neutropaenia were observed 
in 58 out of 771 (7.5%) patients (giving a neutropaenia 
episode rate per 1000 person-months (95% CI) of 4.94 
(3.63 to 6.15)). None of these patients had a diagnosis 
of Felty’s syndrome or large granulocytic leukaemia, 
were receiving medications—apart from DMARDs—
commonly linked to neutropaenia,18 or had a diagnosis 
of solid or haematological malignancy. Neutropaenia 
occurred at a median (range) of 12 (0–120) months 
after the RA diagnosis; in 5 (8.6%) of these patients, it 
was present at the baseline visit. The majority of patients 
had mild neutropaenia (grade 1: n=42 (72.4%); grade 
2: n=14(24.1%); grade 3: n=1 (1.7%); grade 4: n=1 
(1.7%)), with a mean±SD number of neutrophils of 
1.69±0.3×10^9/L across all patient episodes.
laboratory and clinical features associated with neutropaenic 
episodes
At the time of the neutropaenic episode (n=77), coex-
istent leucopaenia was found in 48 (62.3%), lympho-
paenia in 8 (10.4%), thrombocytopaenia in 1 (1.3%) 
and anaemia in 21 (27.3%). None of the patients had 
lymphocytosis (lymphocytes >4.0×10^9/L). At the time 
of neutropaenia, most patients were in remission (47.4%, 
DAS28 <2.6) or had low disease activity (18.6%, DAS28 
<3.2), while only a few had moderate (22.4%, DAS28 >3.2 
and ≤5.1) or high (10.2%, DAS28 >5.1) disease activity.
Comparing baseline characteristics and identifying possible 
predicting factors
Patients who developed neutropaenia were more likely 
to be female (p=0.01) and non-smokers (p=0.007), 
compared with those who did not (table 1). Age, alcohol 
consumption, baseline DAS28 and seropositivity were not 
significantly different between the groups.
Baseline neutrophil levels were also significantly 
lower in patients who subsequently developed neutro-
paenia compared with those who did not (mean±SD: 
4.294±2.116 vs 5.891±2.153, p<0.0001). Further analysis 
revealead that baseline neutrophil counts were signifi-
cantly higher in smokers compared with non-smokers 
(mean±SD: 6.382±2.356 vs 5.548±2.110, p<0.0001) and 
in men compared with women (mean±SD: 6.116±2.274 
vs 5.571±2.143, p=0001). Also, men were more likely to 
be smokers compared with women (32.9% vs 21.1%, 
p<0.0001). Correction for multiple comparisons did not 
affect the statistical significance of any of the abovemen-
tioned values. There were no significant differences in 
baseline counts of total white cells, lymphocytes, plate-
lets or haemoglobin (table 1). Binary logistic regression 
analysis confirmed baseline neutrophil levels as a nega-
tive predictor of neutropaenia development (p=0.001, B: 
−0.491). None of the possible interactions checked were 
found to affect our model (gender by smoking status, 
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Table 2 Cytopaenias observed, treatment received and infections rate throughout the follow-up time
Patient characteristics throughout the 
disease
Neutropaenic
n=58
Non–neutropaenic
n=713 P values
Laboratory
  Anaemia,* n (%) 25 (43.1) 210 (29.5) 0.04
  Thrombopenia,† n (%) 1 (1.7) 5 (0.70) 0.375
  Leucopaenia,‡ n (%) 41 (70.7) 23 (3.43) <0.0001
  Lymphopaenia,§ n (%) 13 (22.4) 98 (13.7) 0.08
Treatment
  Methotrexate, n (%) 52 (89.6) 590/667 (88.4) 1.000
  Sulfasalazine, n (%) 33 (56.9) 342/667 (51.2) 0.494
  Hydroxychloroquine, n (%) 31 (53.4) 345/667 (51.7) 0.891
  Leflunomide, n (%) 3 (5.2) 43/667 (6.4) 1.000
  Azathioprine, n (%) 1 (1.7) 3/667 (0.5) 0.281
  Prednisone oral, n (%) 4 (7.0) 67/667 (10.0) 0.644
  Corticosteroids intramuscularly, n (%) 48 (82.8) 573/667 (80.3) 0.559
  Antitumour necrosis factor, n (%) 5 (8.6) 30/667 (4.5) 0.189
  Abatacept, n (%) 0 (0.0) 3/667 (0.5) 1.000
  Tocilizumab, n (%) 0 (0.0) 11/667 (1.7) 1.000
  Rituximab, n (%) 0 (0.0) 10/667 (1.5) 1.000
Outcomes
  Infections, incidence rate (95% CI)¶ 4.43 (1.62 to 9.66) 3.87 (2.92 to 5.04) 0.878
*Haemoglobin <135 g/L for men and haemoglobin <120 g/L for women.
†Platelets <100×10^9/L
‡White cell count: <4×109/L.
§Lymphocytes: <1×109/L.
¶Incidence rate is expressed as events per 1000 person-months.
p=0.515; baseline neutrophils by smoking status, p=0.175; 
gender by baseline neutrophils, p=0.426). Furthermore 
in a regression analysis having only gender and smoking 
status as covariates, it was found that both male gender 
(p=0.027, B: −0.764) and smoking (p=0.018, B: −1.042) 
were negatively associated with neutropaenia develop-
ment. Additionally, compared with those with grade 1 or 
grade 2 neutropaenia (online supplementary table 2), 
patients with grade 3/4 neutropaenia (analysed as one 
group because of the small number of patients in each of 
these two groups) were older (p=0.02 and p=0.04, respec-
tively) and had higher DAS28 at baseline visit (p=0.018 
and p=0.026, respectively).
Comparing characteristics throughout the disease course
During the total follow-up time, patients who developed 
at least one episode of neutropaenia were also more 
likely to develope anaemia (p=0.04) at some time point, 
but not other blood count abnormalities (table 2). Char-
acteristics or treatment received throughout the disease 
course did not differ among patients with different 
grades of neutropaenia (online supplementary table 2).
dMaRds and steroids
Treatment received for RA did not differ signifi-
cantly between those with or without neutropaenia 
throughout the disease course (table 2). The frequency 
of neutropaenia for the total number of patients with RA 
in our cohort receiving methotrexate, sulfasalazine and 
hydroxychloroquine was 8.1%, 8.8% and 8.2%, and the 
respective rates were 4.92, 6.68 and 5.69 per 1000 persons-
months. Considering all episodes of neutropaenia 
(n=77), 76.4% were on methotrexate (median (range) 
dose: 17 (5–25) mg/week, median (range) exposure 
time: 7.7 (0.5–48.0) months), 47.2% were on sulfasala-
zine (median (range) dose: 2 (0.5–3) g/day, median 
(range) exposure time: 12.0 (1.4–48) months) and 44.4% 
were on hydroxychloroquine (median (range) dose: 200 
(200–400) mg/day, median (range) exposure time: 24.0 
(0.9–48.0) months). In 30.6% and 19.4% of the episodes, 
patients were on combination treatment with 2 and 3 
conventional DMARDs, respectively. Episodes of neutro-
paenia led to treatment discontinuation of the current 
DMARD in 18.1% of cases (14 out of 77). Sulfasalazine 
was stopped permanently in five cases, while metho-
trexate was stopped in nine patients (only temporarily in 
five). No adjustment in treatment was made for patients 
on hydroxychloroquine. No statistically significant differ-
ence was observed in the occurrence of subsequent 
neutropaenic episodes when we compared patients in 
whom treatment with methotrexate and/or sulfasalazine 
was permanently or temporarily discontinued after the 
episode of neutropaenia with those who did not have any 
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treatment adjustments for methotrexate (p=0.423) and 
for sulfasalazine (p=0.304).
The majority (37 of 58; 63.8%) of patients who devel-
oped neutropaenia had received intramuscular steroids 
(either triamcinolone or methylprednisolone) by the 
time of the first episode of neutropaenia. Of these, 18 
(48.6%) had received only one injection, 13 (35.1%) 
had received two, while 6 (16.2%) had received more 
than two intramuscular injections. The mean (±SD) time 
interval between the last intramuscular steroid injection 
and the episode of neutropaenia was 431.2 (±309.9) days, 
and the mean (±SD) cumulative dose of steroids received 
by intramuscular injection prior to the neutropaenia 
episode was 101.5 (±84.1) mg for triamcinolone and 
198.8 (±121.0) mg for methylprednisolone.
In patients who developed neutropaenia, the mean 
cumulative dose of intramuscular steroids received 
throughout the disease course (mean±SD: triamcino-
lone 133.8±36.6 mg; methylprednisolone 230.0±157.0 
mg) did not differ compared with that of patients who 
never developed neutropaenia (mean±SD: triamcin-
olone 144.7±130.1 mg, p=0.979; methylprednisolone 
243.5±157.4 mg, p=0.718). The percentage of patients 
who received intramuscular steroids throughout the 
disease course was also comparable between the two 
groups (neutropaenic: 48 of 58 (82.8%); non-neutro-
paenic: 573 of 667 (80.3%); p=0.559).
Only four of the patients who developed neutropaenia 
had been exposed to oral steroids. None of them were 
receiving oral steroids at the time of neutropaenic 
episode, with a mean (±SD) time interval between the 
discontinuation of steroids and the episode of neutro-
paenia of 240 (±143.1) days. Comparison with patients 
who never developed neutropaenia did not reveal any 
differences in mean exposure time to steroids (mean±SD: 
for neutropaenic: 82.5±9.6 days; for non-neutropaenic: 
90.7±41.1 days; p=0.118) or in percentage of patients who 
had received steroids by mouth throughout the disease 
course (neutropaenic: 4 of 58 (7.0%); non-neutropaenic: 
67 of 667 (10.0); p=0.644). Most of them were exposed to 
tapering high/medium steroid doses. Percentages were 
comparable between the two groups (high/medium 
steroid doses for neutropaenic: 75%/25%; for non-neut-
ropaenic: 73.1%/19.4%; p=1.000).
natural history and outcomes
The majority (44 of 58; 75.8%) of patients with neutro-
paenia had only a single episode (transient neutro-
paenia) recorded. Compared with patients with tran-
sient neutropaenia, those with recurrent episodes were 
found to have more frequent baseline anaemia (p=0.03). 
No other demographic, clinical or laboratory feature, at 
baseline or throughout the disease course, was found to 
differ significantly between the two groups.
Infections were found in temporal association (within 
3 months prior to or after the episode of neutropaenia) 
with neutropaenia in three cases (3.9%). The rate 
of infections per 1000 person-months did not differ 
between patients who developed neutropaenia and those 
who did not ((95% CI), 4.43 (1.62 to 9.96) vs 3.87 (2.92 
to 5.04); p=0.878). The rate of infections was also compa-
rable between patients with transient or recurrent neut-
ropaenia ((95% CI), 3.07 (0.62 to 9.02) vs 7.89 (1.58 to 
23.1), respectively; p=0.443) and between patients with 
different grades of neutropaenia ((95% CI), grade 1: 
5.07 (1.63 to 11.83); grade 2: 2.92 (0.04 to 16.7); grade 3 
- 4: not applicable, p=1.000) (online supplementary table 
2).
dIsCussIOn
Neutropaenia is a recognised finding in patients with 
RA, but its true incidence is not well defined, particularly 
in early RA. Its pathogenesis can be multifactorial, with 
several mechanisms proposed, namely (1) autoimmune 
neutropaenia in the context of RA where antigranulo-
cyte antibodies are sometimes present, (2) bone marrow 
failure, (3) Felty’s syndrome, (4) large granulocytic 
lymphocyte leukaemia, (5) viral infections and (6) medi-
cations.6
Herein, we estimated the frequency of neutropaenia 
in patients with newly diagnosed RA who were DMARD-
naïve at recruitment (baseline) and treated in line with 
standard clinical practice. It was found that 7.5% of 
patients with RA developed at least one episode of neut-
ropaenia during follow-up (median 18 months). Our 
results are also consistent with previous cohorts where 
neutropaenia in untreated patients with RA was found to 
be very low: –0.65% of patients in our cohort had neutro-
paenia at baseline.2
In line with previous studies which reported low neutro-
phil counts in about 2%–10% and 1.8%–12.5% of patients 
treated with sulfasalazine11 12 19 and methotrexate,8 14 20 
respectively, in our cohort this frequency was found to 
be about 8% for each drug. The median exposure time 
to these drugs, in patients who developed neutropaenia, 
in our study was more than 6 months, suggesting, as 
previously reported, that neutropaenia occurrence 
was not always an immediate effect of the medication 
received.7 8 Sulfasalazine or methotrexate was tempo-
rarily or permanently discontinued in about 20% of cases 
of neutropaenia in our study. Prednisone is recognised to 
increase leucocyte, and particularly neutrophil, count by 
a number of potential mechanisms.21–23 However, in our 
study treatment with oral or intramuscular steroids did 
not affect the occurrence of neutropaenia, with compa-
rable steroid exposure and doses between patients who 
developed neutropaenia and those who did not.
Although there are no studies specifically designed to 
explore this, methotrexate and sulfasalazine are drugs 
thought to be most associated with increased neutro-
paenia occurrence in RA.6 8 24 In fact, in a large study 
analysing the computer records of patients with RA who 
were on monotherapy with DMARDs, neutropaenia was 
found to be equally common for these two drugs.8 The 
existing DMARD guidelines suggest to monitor blood 
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regularly (every 2–4 weeks for the first 1–3 months and 
then less frequently (eg, every 4–12 weeks)).25–27 Guide-
lines on prescription and monitoring of non-biologic 
DMARDs generally advise that the perscriber—if this is 
different from the treating clinician—should contact the 
rheumatology team and consider treatment discontin-
uation if neutrophils drop below 1.600/μL or the total 
white cell count is below 3.500/μL.25 In previous guide-
lines it was also suggested not to start methotrexate or 
leflunomide in patients whose white cell counts are below 
3.000/μL.28
Published reports for neutropaenia with biologic drugs 
range from 14.3% to 19%.1 3 4 However, for some, such 
as rituximab, this association may be difficult to assess 
due to delayed onset of neutropaenia following treat-
ment.29 30 In our cohort, the small percentage of patients 
treated with biologics precluded further analysis about 
the possible association between neutropaenia and expo-
sure to biologics. There were no patients on Janus Kinase 
(JAK) inhibitors. While neutropaenia may be anticipated 
based on their biologic action,31 data available from long-
term extension studies suggest that this is encountered 
in only about 5% of patients and is mainly of grade 1.32 33
Interestingly, patients who developed neutropaenia 
in our cohort were more likely to have anaemia, but 
not other cytopaenias, throughout the disease course. 
Furthermore, patients with recurrent neutropaenia were 
more likely to have baseline anaemia, compared with 
those who only had a single recorded occurrence of neut-
ropaenia. This could suggest that bone marrow suppres-
sion may be a contributing factor. However, bone marrow 
studies were not performed or required in any of these 
patients, so this cannot be confirmed. That said, there is 
a growing literature describing the inflammatory context 
of the RA bone marrow,34 35 and future studies to explore 
these mechanisms are warranted.
Further analysis comparing patients with different 
grades of neutropaenia suggested that patients with more 
severe neutropaenia (grade 3/4) were more likely to be 
older and have higher disease activity at baseline visit. This 
analysis has to be interpreted with caution, as the group of 
patients with grade 3/4 neutropaenia included only two 
patients in this cohort. These results could be partially 
explained by the fact that older people—especially in 
the context of an autoimmune rheumatic disease—seem 
to be more prone to develop neutropaenia.24 Various 
factors have been proposed to contribute to this increase 
with age, including comorbidities, bone marrow suppres-
sion and aberrant drug metabolism.24
This study also attempted to identify possible predic-
tors for the development of neutropaenia. We found 
that women, non-smokers and those with lower baseline 
neutrophil counts were more likely to develop neutro-
paenia. A positive relationship between smoking and 
increased numbers of white cells and/or neutrophils 
has been reported previously36 37 and was also observed 
in our cohort, with higher baseline neutrophil counts in 
smokers compared with non-smokers. Also, in our cohort 
men were more likely to be smokers and to have higher 
baseline neutrophil counts. Thus, it might be possible 
that the observed association between non-smoking, 
female gender and the development of neutropaenia is 
confounded by non-smokers’ lower baseline neutrophil 
levels. Interactions between the aforementioned factors 
did not affect the binary logistic regression analysis, which 
confirmed only baseline neutrophil levels as predictor 
for subsequent neutropaenia development. On the other 
hand, a regression analysis with only male gender and 
smoking status as independent variables suggested that 
both are negatively associated with neutropaenia occur-
rence. These findings are consistent with studies in the 
oncology literature suggesting that smoking might act 
as a protective factor for chemotherapy-induced neutro-
paenia, which has been attributed to the possible epigen-
etic effects of smoke on cytochrome P450 enzymes.38–40 
Furthermore, there is also some evidence from oncology 
studies that female gender may be a risk factor for neutro-
paenia development.41 42 Therefore, the possible associa-
tion of smoking and male gender with reduced frequency 
of neutropaenia in RA warrants further investigation.
Reassuringly, neutropaenia in the context of early RA 
was not associated with a significantly increased rate of 
infections, most probably reflecting the fact that neutro-
paenia in our cohort was mostly mild. However, it should 
be noted that a possible difference in the frequency 
of infections could be missed as a result of the small 
number (n=58) of patients with at least one episode of 
neutropaenia.
We acknowledge that our study has certain limitations. 
First, it is possible that episodes of neutropaenia have 
been missed between the 6-monthly visits. Although this 
timing reflects the real-world practice for some patients 
with RA, the follow-up for early RA is more intense in 
clinical practice, and therefore the frequency of neutro-
paenia might have been underestimated in our cohort. 
Second, our cohort does not include many patients on 
biologic treatment, as it is an inception RA cohort. Thus, 
no conclusions can be made for neutropaenia in patients 
treated with biologic drugs. Third, the presence of anti-
nuclear or other autoantibodies and certain important 
extra-articular manifestations (eg, sicca manifestations) 
were not recorded in our cohort. Therefore, occurrence 
of secondary autoimmune rheumatic diseases could not 
be defined. However, as described earlier, patients with 
existing alternative rheumatic diagnosis at baseline (eg, 
psoriatic arthritis, primary Sjogren’s, systemic lupus 
erythematosus) were excluded, as were participants 
whose diagnosis was revised by their treating rheumatolo-
gist during the follow-up period.
In summary, in our cohort, while at least one episode 
of neutropaenia was recorded in 7.5% of patients with 
early RA, this was generally mild and was not associated 
with increased infections. The strongest predictor for the 
occurrence of subsequent neutropaenia was the base-
line neutrophil level, while a possible protective role of 
smoking and male gender warrants further investigation.
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